Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
| Revenue (TTM) | $2.59B |
| Gross Profit (TTM) | $1.35B |
| EBITDA | $441.00M |
| Operating Margin | 11.20% |
| Return on Equity | 3.11% |
| Return on Assets | 1.66% |
| Revenue/Share (TTM) | $96.20 |
| Book Value | $268.30 |
| Price-to-Book | 1.33 |
| Price-to-Sales (TTM) | 3.67 |
| EV/Revenue | 3.545 |
| EV/EBITDA | 16.17 |
| Quarterly Earnings Growth (YoY) | 18.70% |
| Quarterly Revenue Growth (YoY) | -0.10% |
| Shares Outstanding | $21.70M |
| Float | $20.89M |
| % Insiders | 16.36% |
| % Institutions | 91.42% |
Volatility is currently contracting
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.
I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius.
U.S. biotechnology industry trade group BIO worked with the Food and Drug Administration on plans announced on Monday to speed clinical trials and expects the next initiative will aim to standardize the agency's review of drug applications, CEO John Crowley said on Tuesday.
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price, the Wall Street Journal reported on Sunday.
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Format: Fireside chat and one-on-one investor meetings Participants: Roop K. Lakkaraju, Chief Financial Officer Date and Time: Tuesday, May 19, 2026, at 8:30 AM Eastern Time; a live webc.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIO and any ticker you trade — then tracks every position and per-strategy win rate.
